Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes , chronic myelomonocytic leukemia , or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.
http://www.medicalnewstoday.com/releases/258088.php
http://www.medicalnewstoday.com/releases/258088.php
No comments:
Post a Comment